程序性细胞死亡受体 1 在肺癌中的作用。
The Role of Programmed Cell Death Receptor 1 in Lung Cancer.
机构信息
General Surgery Department, "Bagdasar Arseni" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Department of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania;
出版信息
In Vivo. 2022 Mar-Apr;36(2):1007-1012. doi: 10.21873/invivo.12794.
BACKGROUND/AIM: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear.
PATIENTS AND METHODS
This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage.
RESULTS
Patients were diagnosed with non-microcellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PD-L1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%.
CONCLUSION
No correlation was found between PD-L1 tumor expression and the age and sex of patients.
背景/目的：肺癌是全球最常见的癌症。癌症免疫疗法是激活免疫系统对抗癌症。最新的免疫疗法方法涉及免疫检查点抑制剂。在非小细胞肺癌中观察到程序性死亡配体 1（PD-L1）表达水平升高。PD-L1 表达与肺癌临床病理特征之间的关系尚不清楚。
患者和方法
这是一项横断面观察性研究，评估了 2019 年 3 月至 2020 年 12 月期间诊断的 41 例肺癌患者的样本。PD-L1 肿瘤表达以百分比表示。
结果
患者被诊断为非微细胞肺癌，年龄在 37 至 87 岁之间。大多数患者被诊断为腺癌。根据分析，阴性 PD-L1 肿瘤患者的平均年龄为 65.6 岁，阳性 PD-L1 肿瘤患者的平均年龄为 63.6 岁。男性肿瘤比例评分的平均值为 26.97%，女性为 25.55%。
结论
PD-L1 肿瘤表达与患者的年龄和性别之间没有相关性。
Zotero 插件